Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues

Journal of Cellular Physiology

Volumn 210, Issue 1, 2007, Pages 111-121

  Zhao, Hongjuan ^a   Ramos, Cristiane F ^b   Brooks, James D ^a   Peehl, Donna M ^a,c  

^a STANFORD UNIVERSITY   (United States)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOTOXIN GENE; CELL ACTIVITY; CELL ADHESION; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DNA MICROARRAY; DOWN REGULATION; ENPP2 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MALE; MICROARRAY ANALYSIS; PERIPHERAL ZONE CELL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; PROSTATE STROMA CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; S100A4 GENE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROMA CELL; SULF1 GENE; TISSUE SECTION; TRANSCRIPTION REGULATION; TRANSITION ZONE CELL; UPREGULATION;

ADULT; AGED; BLOTTING, WESTERN; CELLS, CULTURED; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; S100 PROTEINS; STROMAL CELLS; SULFOTRANSFERASES; TRANSCRIPTION, GENETIC;

EID: 33845389417     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20828     Document Type: Article

References (53)

1. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR. 2003. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 9(13):4792-4801.
2. Barclay WW, Woodruff RD, Hall MC, Cramer SD. 2005. A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 146(1):13-18.
3. Black EJ, Clair T, Delrow J, Neiman P, Gillespie DA. 2004. Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun. Oncogene 23(13):2357-2366.
4. Brindley DN. 2004. Lipid phosphate phosphatases and related proteins: Signaling functions in development, cell division, and cancer. J Cell Biochem 92(5):900-912.
5. Brooks JD. 2002. Microarray analysis in prostate cancer research. Curr Opin Urol 12(5):395-399.
6. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. 2004. Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2(2):E7.
7. Chung LW, Cunha GR. 1983. Stromal-epithelial interactions: II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 4(5):503-511.
8. Chung LW, Baseman A, Assikis V, Zhau HE. 2005. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 173(1):10-20.
9. Condon MS. 2005. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 15(2):132-137.
10. Cunha GR. 1984. Androgenic effects upon prostatic epitheliium are mediated via trophic influences from stroma. In: Kimball FA, Gary Stein, Car DB, editor. New approaches to the study of benign prostatic hyperplasia. New York: Liss. pp 81-102.
11. Cunha GR, Reese BA, Sekkingstad M. 1980. Induction of nuclear androgen-binding sites in epithelium of the embryonic urinary bladder by mesenchyme of the urogenital sinus of embryonic mice. Endocrinology 107(6):1767-1770.
12. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer L, Reese BA. 1983a. Epithelial-mesenchymal interactions in prostatic development. I. morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 96(6):1662-1670.
13. Cunha GR, Sekkingstad M, Meloy BA. 1983b. Heterospecific induction of prostatic development in tissue recombinants prepared with mouse, rat, rabbit and human tissues. Differentiation 24(2):174-180.
14. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. 1987. The endocrinology and developmental biology of the prostate. Endocr Rev 8(3):338-362.
15. Cunha GR, Hayward SW, Wang YZ. 2002. Role of stroma in carcinogenesis of the prostate. Differentiation 70(9-10):473-485.
16. Cunha GR, Hayward SW, Wang YZ, Ricke WA. 2003. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107(1):1-10.
17. Fromont G, Chene L, Latil A, Bieche I, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Cussenot O. 2004. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase- polymerase chain reaction approach. J Urol 172(4 Pt 1):1382-1385.
18. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. 2004. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 279(17):17634-17639.
19. Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR. 2001. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 61(22):8135-8142.
20. Isaacs JT, Coffey DS. 1989. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 2:33-50.
21. Iwano M, Fischer A, Okada H, Plieth D, Xue C, Danoff TM, Neilson EG. 2001. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther 3(2):149-159.
22. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110(3):341-350.
23. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. 2005. Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res 65(22):10423-10430.
24. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. 2003. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278(25):23107-23117.
25. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V. 2004a. HSulf-1 modulates HGF.mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23(7):1439-1447.
26. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, Greene EL, Shridhar V, Roberts LR. 2004b. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126(1):231-248.
27. Lamm ML, Catbagan WS, Laciak RJ, Barnett DH, Hebner CM, Gaffield W, Walterhouse D, Iannaccone P, Bushman W. 2002. Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation. Dev Biol 249(2):349-366.
28. Lee KL, Peehl DM. 2004. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 172(5 Pt 1):1784-1791.
29. Lipinski RJ, Cook CH, Barnett DH, Gipp JJ, Peterson RE, Bushman W. 2005. Sonic hedgehog signaling regulates the expression of insulin-like growth factor binding protein-6 during fetal prostate development. Dev Dyn 233(3):829-836.
30. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB. 2001. Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. Cancer Res 61(12):4683-4688.
31. McNeal JE. 1978. Origin and evolution of benign prostatic enlargement. Invest Urol 15(4):340-345.
32. McNeal J. 1990. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 17(3):477-486.
33. Moolenaar WH, van Meeteren LA, Giepmana BN. 2004. The ins and outs of lysophosphatidic acid signaling. Bioessays 26(8):870-881.
34. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML. 2001. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 61(18):6938-6944.
35. Nelson PS. 2004. Predicting prostate cancer behavior using transcript profiles. J Urol 172(5 Pt 2):S28-S32; discussion S33.
36. Okada H, Danoff TM, Kalluri R, Neilson EG. 1997. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273(4 Pt 2):F563-F574.
37. Peehl DM, Sellers RG. 2000. Cultured stromal cells: An in vitro model of prostatic mesenchymal biology. Prostate 45(2):115-123.
38. Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, Caldwell M, Peehl DM. 2005. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett 227(2):213-222.
39. Sala-Newby GB, George SJ, Bond M, Dhoot GK, Newby AC. 2005. Regulation of vascular smooth muscle cell proliferation, migration and death by heparan sulfate 6-O-endosulfatase1. FEBS Lett 579(28):6493-6498.
40. San Francisco IF, DeWolf WC, Peehl DM, Olumi AF. 2004. Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer 112(2):213-218.
41. Shapiro E, Becich MJ, Hartanto V, Lepor H. 1992. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147(5):1293-1297.
42. Sherlock G, Hernandez-Boussard T, Kasarskis A, Binkley G, Matese JC, Dwight SS, Kaloper M, Weng S, Jin H, Ball CA, Eisen MB, Spellman PT, Brown PO, Botstein D, Cherry JM. 2001. The Stanford microarray database. Nucleic Acids Res 29(1):152-155.
43. Song J, Clair T, Noh JH, Eun JW, Ryu SY, Lee SN, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, Nam SW, 2005. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. Biochem Biophys Res Commun 337(3):967-975.
44. Stamey TA, Caldwell MC, Fan Z, Zhang Z, McNeal JE, Nolley R, Chen Z, Mahadevappa M, Warrington JA. 2003. Genetic profiling of Gleason grade 4/5 prostate cancer: Which is the best prostatic control tissue? J Urol 170(6 Pt 1):2263-2268.
45. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, Neilson EG. 1995. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130(2):393-405.
46. Tusher VG, Tibshirani R, Chu G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116-5121.
47. Tuxhorn JA, Ayala GE, Rowley DR. 2001. Reactive stroma in prostate cancer progression. J Urol 166(6):2472-2483.
48. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. 2002a. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8(9):2912-2923.
49. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR. 2002b. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res 62(11):3298-3307.
50. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. 2002. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):227-233.
51. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP, Jr. 2004. QSulf1, a heparan sulfate 6-0-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 101(14):4833-4838.
52. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M. 2004. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 166(1):107-113.
53. Zhao H, Lai F, Nonn L, Brooks JD, Peehl DM. 2005. Molecular targets of doxazosin in human prostatic stromal cells. Prostate 62(4):400-410.